Absent preoperative non-small cell lung cancer confirmation and relevant stage migration in the era before neoadjuvant chemoimmunotherapy: implications for treatment decisions in resectable non-small cell lung cancer

In the era before the introduction of neoadjuvant chemoimmunotherapy as standard of care, absent preoperative NSCLC confirmation or inaccurate staging occurred in nearly a quarter of potential candidates for neoadjuvant treatment. These two limiting factors will need to be addressed in order to adequately administer neoadjuvant therapy in patients with resectable NSCLC conform current guidelines.

Authors

Institutions

Publication Details

Journal
Translational Lung Cancer Research
Published
2025-05-01
DOI
https://doi.org/10.21037/tlcr-2024-1120
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Absent preoperative non-small cell lung cancer confirmation and relevant stage migration in the era before neoadjuvant chemoimmunotherapy: implications for treatment decisions in resectable non-small cell lung cancer

Francesco Ciompi, Guus R. M. van den Heuvel, Olga C.J. Schuurbiers, Erik H.J.G. Aarntzen et al.
Translational Lung Cancer Research
Lung Cancer Treatments and Mutations
article

Absent preoperative non-small cell lung cancer confirmation and relevant stage migration in the era before neoadjuvant chemoimmunotherapy: implications for treatment decisions in resectable non-small cell lung cancer

Francesco Ciompi, Guus R. M. van den Heuvel, Olga C.J. Schuurbiers, Erik H.J.G. Aarntzen, Hans J.M. Smit, Michel M. van den Heuvel, Iris Walraven, Kaamar Azijli, Bas L R Mandos
article en

Abstract

In the era before the introduction of neoadjuvant chemoimmunotherapy as standard of care, absent preoperative NSCLC confirmation or inaccurate staging occurred in nearly a quarter of potential candidates for neoadjuvant treatment. These two limiting factors will need to be addressed in order to adequately administer neoadjuvant therapy in patients with resectable NSCLC conform current guidelines.

Translational Lung Cancer ResearchVol. 14(5)
Radboud University Nijmegen (NL), Radboud University Medical Center (NL)
Amgen, Pfizer, AstraZeneca, Genentech
Openalex Percentile: Top 80%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Absent preoperative non-small cell lung cancer confirmation and relevant stage migration in the era before neoadjuvant chemoimmunotherapy: implications for treatment decisions in resectable non-small cell lung cancer — Francesco Ciompi, Guus R. M. van den Heuvel, et al. · Translational Lung Cancer Research (2025) | TGRS Research Map | TGRS